Annexon, Inc. (ANNX) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.67
↑+64% vs avg
5yr avg: 1.63
30Y Low1.2·High2.4
ROE
↓
-50.8%
-3% vs avg
5yr avg: -49.2%
30Y Low-91%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANNX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Annexon, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $624M | $705M | $344M | $283M | $440M | $425M | — | — | — |
| Enterprise Value | $603M | $684M | $150M | $176M | $400M | $156M | — | — | — |
| P/E Ratio → | -5.65 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.67 | 2.40 | 1.37 | 1.22 | 1.90 | 1.23 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ANNX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
ANNX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -50.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.8% | -50.8% | -55.7% | -61.3% | -45.2% | -32.7% | -91.3% | -48.3% | — |
| ROA | -42.7% | -42.7% | -46.1% | -49.6% | -40.5% | -31.2% | -75.8% | -65.4% | -239.2% |
| ROIC | -70.2% | -70.2% | -119.2% | -69.2% | -73.3% | -126.4% | -48.5% | -28.5% | — |
| ROCE | -51.4% | -51.4% | -53.0% | -55.1% | -42.8% | -32.5% | -72.4% | -77.0% | -417.5% |
ANNX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $49M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.13 | 0.14 | 0.15 | — | — | 2.83 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.07 | -0.77 | -0.46 | -0.17 | -0.78 | -1.01 | 1.66 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($49M) exceeds total debt ($29M)
ANNX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Annexon, Inc.'s current ratio of 10.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.10x to 10.37x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.37 | 10.37 | 14.72 | 11.10 | 11.39 | 33.33 | 9.21 | 13.74 | 1.68 |
| Quick Ratio | 10.37 | 10.37 | 14.72 | 11.10 | 11.39 | 33.33 | 9.21 | 13.74 | 1.68 |
| Cash Ratio | 10.23 | 10.23 | 14.49 | 10.85 | 11.16 | 33.06 | 8.91 | 13.28 | 1.02 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
ANNX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Annexon, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 1.5% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.5% | — | — | — |
| Shares Outstanding | — | $137M | $76M | $55M | $38M | $17M | $38M | $11M | $38M |
Peer Comparison
Compare ANNX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANNXYou | $624M | -5.6 | — | — | — | — | -50.8% | -70.2% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 APLS | $5B | 228.4 | 92.7 | 116.9 | 89.8% | 5.5% | 7.5% | 12.3% | 8.5 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ANNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANNX vs BEAM
Side-by-side business, growth, and profitability comparison vs Beam Therapeutics Inc..
Start ComparisonANNX — Frequently Asked Questions
Quick answers to the most common questions about buying ANNX stock.
What is Annexon, Inc.'s P/E ratio?
Annexon, Inc.'s current P/E ratio is -5.6x. This places it at the 50th percentile of its historical range.
What is Annexon, Inc.'s ROE?
Annexon, Inc.'s return on equity (ROE) is -50.8%. The historical average is -55.1%.
Is ANNX stock overvalued?
Based on historical data, Annexon, Inc. is trading at a P/E of -5.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.